WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testin... (fected by these actions. WuXi ...)

WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services

Date:12/2/2008

fected by these actions."

WuXi expects to record (i) cash restructuring charges, estimated to total approximately $2.5 to $3.5 million, consisting primarily of severance and other employee-related charges and to be payable over the next few months; and (ii) non-cash charges for impairment of certain fixed and intangible assets, including goodwill. WuXi currently is working with external consultants to determine an estimate for the non-cash impairment charges as a result of the restructuring.

Conference Call

WuXi PharmaTech's senior management will host a conference call at 8:00 a.m. (Eastern) / 5:00 a.m. (Pacific) / 9:00 p.m. (Beijing/Hong Kong) on December 2, 2008, to discuss today's announcement. The conference call may be accessed by dialing:

    (US) 866-586-2813
    (China, Northern Region) 10-800-611-0127
    (China, Southern Region) 10-800-361-0079
    (HK) 800-965-808
    (UK) 0-800-056-9662
    (International) +61-2-8524-6650
    Conference ID: 75793921

    A telephone replay will be available two hours after the call's completion
until December 9, 2008, at:

    (US) 866-214-5335
    (HK) 800-901-596
    (China) 10-800-140-0386
    (UK) 0-800-731-7846
    (International) +61-2-8235-5000
    Passcode: 75793921

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec

Post Your Comments:

WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testin...(fected by these actions. WuXi ...)